Colorectal Cancer

There’s a new standard of care in the first-line setting for a subset of patients with advanced colorectal cancer.
The combination of the PD-1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab added to best supportive care improved overall survival (OS) by >2 months compared with best supportive care alone in a phase 2 randomized trial of unselected patients with refractory colorectal cancer (CRC).
More targeted therapy options make their way into the updated guideline (version 1.2019) from the National Comprehensive Cancer Network (NCCN) for the management of metastatic colorectal cancer (CRC).
Updated results from the safety lead-in of the phase 3 BEACON CRC clinical trial show a mature median overall survival (OS) of 15.3 months with the triple-drug regimen of encorafenib, a BRAF inhibitor; binimetinib, a MEK inhibitor; and cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation.
Using a “double whammy” of 2 HER2-directed therapies achieved a clinical benefit rate of 70% and an objective response rate (ORR) of 30% in patients with heavily pretreated, HER2-positive metastatic colorectal cancer (CRC), according to final results from the phase 2 HERACLES-A trial.
Adding vemurafenib to cetuximab and irinotecan prolonged progression-free survival (PFS) and improved the disease control rate in patients with BRAF V600E mutation–positive colorectal cancer (CRC).
Here is new information pertaining to this disease site for genetic testing and practice guidelines.
Partnerships between churches and universities have emerged as a promising approach for addressing public health inequities. EPICS is a community outreach and screening program.
Page 1 of 2
Results 1 - 10 of 16

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State